The specter of generic challenges has repeatedly loomed around copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of similar medicinal investments. While initial times saw substantial profits, the patent lapse has created the way for less expensive alternatives, likely lowering revenue and presenting a genuine hazard